We are live on ! Find out more

RBOT

Vicarious Surgical

RBOT

Market cap $13.7M

Delisted

RBOT was delisted on the 2nd of March, 2026.

Back to rankings

About: Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.

Employees: 131

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 0%

Negative 0%

Vicarious Surgical Receives Delisting Notice From NYSE

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the “Common Stock”). Trading on the Company's Common Stock on the NYS.

Vicarious Surgical Receives Delisting Notice From NYSE

NYSE to Commence Delisting Proceedings Against Vicarious Surgical Inc. (RBOT)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of Vicarious Surgical Inc. (the “Company”) — ticker symbol RBOT — from the NYSE. Trading in the Company's Class A common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company's Class A common stock pursuant to Section 802.01B of the NYSE's Listed Compan.

NYSE to Commence Delisting Proceedings Against Vicarious Surgical Inc. (RBOT)

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed.

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

Zacks Investment Research

RBOT Enters Strategic Software Partnership to Streamline Development

Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.

RBOT Enters Strategic Software Partnership to Streamline Development

Vicarious Surgical Announces Strategic Software Execution Partnership to Streamline Operations

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company's broader operating model transformation, designed to improve execution, increase development predictabil.

Vicarious Surgical Announces Strategic Software Execution Partnership to Streamline Operations

NYSE to Commence Delisting Proceedings with Respect to Warrants of Vicarious Surgical Inc. (RBOT WS)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants (“Warrants”) — ticker symbol RBOT WS — thirty (30) whole warrants are exercisable to purchase one share of Class A common stock of Vicarious Surgical Inc. (the “Company”) from the NYSE. Trading in these Warrants on the NYSE will be suspended immediately. Trading in the Company's Class A common stock — tick.

NYSE to Commence Delisting Proceedings with Respect to Warrants of Vicarious Surgical Inc. (RBOT WS)

Vicarious Surgical Announces Full Year 2026 Cash Burn Guidance

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced its full-year 2026 cash burn guidance. Vicarious Surgical expects full-year 2026 cash burn of approximately $35 million, representing a $10 million improvement from the Company's recently updated 2025 guidance of $45 million. Cash needs beyond existing cash resources to achieve desi.

Vicarious Surgical Announces Full Year 2026 Cash Burn Guidance

Vicarious Surgical Announces Reduction in 2025 Cash Burn Outlook

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced an update to full-year 2025 financial guidance. Vicarious Surgical now expects full-year 2025 cash burn of approximately $45 million, representing a $5 million improvement from its previous guidance of $50 million. The improved guidance reflects disciplined cost management initiativ.

Vicarious Surgical Announces Reduction in 2025 Cash Burn Outlook

Vicarious Surgical to Participate in the Piper Sandler 37th Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that the Company will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference. Vicarious Surgical's management is scheduled to participate in a fireside discussion on Wednesday, December 3, 2025, at 4:30 p.m. Eastern Standard Time. Interes.

Vicarious Surgical to Participate in the Piper Sandler 37th Annual Healthcare Conference

Vicarious Surgical Inc. (RBOT) Q3 2025 Earnings Call Transcript

Vicarious Surgical Inc. ( RBOT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Stephen From - CEO & Director Sarah Romano - CFO & Treasurer Conference Call Participants Marissa Bych - Gilmartin Group LLC Joshua Jennings - TD Cowen, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon. Thank you for attending the Vicarious Surgical's 2025 Third Quarter Earnings Call.

Vicarious Surgical Inc. (RBOT) Q3 2025 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™